RankAlpha logo
Back to Rankings

NSPR

InspireMDF
Nasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
View Chart
Current thesis
International Q2 revenue grew 21% year over year despite the U.S. recall, and management is pursuing two U.S.
Posture
Defensive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-11-12 · BMO.
What can break
Cash and marketable securities declined from $54.2 million at December 31, 2025 to $30.4 million at June 30, 2026, making spending and financing needs important to monitor. [#SEC-8K-2026-08-17]
Momentum
46
Value
36
Sentiment
38
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.55 · Bull $1.10 · Bear $0.20Analysis 2026-10-10; returns require an exact persisted reference.
Earnings
2026-11-12 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-11-06 • Vendor: Data Vendor v1
Scores
As of 2026-11-06 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-10 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-11-06

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-11-06. Definitions

Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $3.33
Why
Momentum46 · Δ7d -
Value36 · Δ7d -20.1
Sentiment38 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

  • • Next scheduled catalyst: earnings 2026-11-12 · BMO.
  • • Value remains the lead driver in the composite, 7D delta -20.1.

Contradictions & invalidation

  • • Cash and marketable securities declined from $54.2 million at December 31, 2025 to $30.4 million at June 30, 2026, making spending and financing needs important to monitor. [#SEC-8K-2026-08-17]
  • • FDA decisions and the recalled 135 cm system's submission may slip or fail; neither approval nor a U.S. relaunch is assured. [#SEC-8K-2026-08-17]
  • • The recall produced $734,000 of U.S.

Catalyst clock

2026-11-12 · BMO

CGuard Prime 80 cm FDA decision

Lead driver: Value · See fundamentals
Momentum
46
18% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
36
43% active weight
Current posture
7d trendSoftening
Δ7d
-20.1
Δ21d
-20.1
Sentiment
38
39% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade F. Momentum 46.3 / Value 36.4 / Sentiment 37.9

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-10. Scenario method

B+
Bull case
25%
Probability
Target price
$1.10
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$0.55
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.20
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-11-06
Market Cap
$32.36M
Beta
0.93
Shares Out
46.49M
P/E (TTM) · Derived
-0.9
P/S (TTM)
10.51
P/FCF (TTM) · Derived
-1.33
Rev YoY
-0.4%
EPS YoY
-34.4%
Gross Margin
+18.1%
Op Margin
-494.0%
Net Debt
-$50.92M
Current Ratio
3.80
As of 2026-11-06 • Updated nightlySource: Internal modelMethods & Data